乌茶辛丸治疗腰椎间盘突出继发坐骨神经痛的等效性随机对照试验
结果显示两组下腰痛及放射痛改善在6周和10周时均落在等效界值内,功能与生活质量无统计学差异,UCSGH相关不良事件频率更低。
要点
- UCSGH在改善LHIVD患者下腰痛和放射痛方面与洛索洛芬等效。
- 两组功能与生活质量改善无统计学差异,UCSGH安全性较好。
- UCSGH可作为LHIVD的补充治疗选择。
核心结论
- UCSGH在减轻LHIVD患者下腰痛和放射痛方面与洛索洛芬达到等效水平,且安全性足够,可作为补充治疗选择。
研究设计与样本
- 试验组口服UCSGH颗粒2.5 g、对照组口服洛索洛芬60 mg片,均每日三次、疗程6周。
- 两组均每周接受一次相同针灸治疗,共6周;在基线及筛选后3、6、10周评估疗效与安全性。
主要发现
- 两组下腰痛从基线变化均值差的95%CI在第6周(9.26, 8.37)和第10周(9.03, 9.62)均在等效界值内。
- 两组放射痛从基线变化在第6周(95%CI:1.70, 15.69)和第10周(95%CI:4.72, 13.75)均在等效界值内。
- 功能与生活质量指标组间无统计学差异。
- 与干预相关的不良事件频率在UCSGH组更低。
关键数值与推荐
- 主要结局为下腰痛从基线变化均值差的95%CI在第6周(9.26, 8.37)和第10周(9.03, 9.62)落在等效界值内。
- 放射痛从基线变化在第6周(95%CI:1.70, 15.69)和第10周(95%CI:4.72, 13.75)落在等效界值内。
- UCSGH颗粒2.5 g每日三次、洛索洛芬60 mg片每日三次,均联合每周一次针灸,疗程6周。
临床怎么用
- 对LHIVD继发下腰痛和放射痛患者,可考虑UCSGH作为洛索洛芬的等效替代或补充治疗。
- 使用UCSGH时可联合针灸治疗,疗程参考6周。
- UCSGH相关不良事件频率较低,安全性可接受。
局限性
- 两组均联合针灸治疗,无法单独评价UCSGH的效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to establish the clinical evidence regarding the effectiveness and safety of Uchasingihwan (UCSGH) in improving pain, function, and quality of life in patients with lumbar herniated intervertebral disc (LHIVD). METHODS: This was a multicenter, randomized, controlled, equivalence trial with two parallel arms. Seventy-four participants with LHIVD were recruited and randomly allocated to the experimental and control groups. The participants in each group took 2.5 g of UCSGH granule or loxoprofen 60 mg tablet three times a day for six weeks. Additionally, both groups received the same acupuncture treatment once a week for six weeks. Outcomes about effectiveness and safety were assessed at baseline and 3, 6, and 10 weeks after screening. RESULTS: As the primary outcome, the mean differences with a 95 % confidence interval (CI) of changes in low back pain between the two groups at weeks 6 (95 % CI:9.26, 8.37) and 10 (95 % CI:9.03, 9.62) from baseline were within the equivalence limit. Also, changes in radiating pain at weeks 6 (95 % CI:1.70, 15.69) and 10 (95 % CI:4.72, 13.75) were within the equivalence limit. Outcome measures for function and quality of life also showed no statistical difference. Regarding safety, the frequency of adverse events related to intervention was lower in UCSGH. CONCLUSION: UCSGH showed the equivalent level of effectiveness as loxoprofen in reducing low back and radiating pain in LHIVD patients and showed sufficient safety to be used as a complementary treatment option. TRIAL REGISTRATION: ClinicalTrials.gov (NCT03386149), CRIS (KCT0002848).
引用
- Goo B, Kim JH, Kim EJ, et al. Clinical research on the effectiveness and safety of Uchasingihwan for low back pain with radiculopathy caused by herniated intervertebral disc of the lumbar spine: A multicenter, randomized, controlled equivalence trial. Integr Med Res. 2024. PMID: 39640075. doi:10.1016/j.imr.2024.101090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。